Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial save search
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
TCON | $1.895 2.43% 2.37% 65K
|
Health Technology
|
| O: -2.27%
H: 1.11%
C: -44.57%
update ongoing pharmaceuticals trial
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
Published: 2024-04-03 (Crawled : 12:00) - prnewswire.com
HRMY | $29.205 1.23% 1.22% 370K
|
Health Technology
|
| O: 0.03%
H: 2.9%
C: -3.09%
global trial
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
CANF | $1.94 -1.52% 0.0% 5.7K
|
Health Technology
|
| O: 2.45%
H: 0.87%
C: -0.43%
fda namodenoson application trial
LUXH FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages LuxUrban Hotels, Inc. Investors to Secure Counsel Before Important April 12 Deadline in Securities Class Action - LUXH
Published: 2024-04-02 (Crawled : 00:00) - prnewswire.com
LUXH | $0.9505 9.25% 8.47% 330K
|
|
| O: -0.71%
H: 2.86%
C: -2.86%
BCDRF | $4.978 -8.71% 100
|
Finance
|
| O: 3.9%
H: 4.33%
C: 4.33%
SHLS | $8.485 0.3% 0.29% 2.8M
|
|
| O: 0.19%
H: 2.0%
C: 0.84%
SAN | $5.05 1.2% 0.0% 4.9M
|
Finance
|
| O: 1.04%
H: 1.23%
C: 0.82%
deadline trial
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Published: 2024-04-02 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 2.01%
H: 4.61%
C: 0.0%
mn-166 presentation meeting trial results glioblastoma
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
SGHT | $5.64 0.0% 85K
|
|
| O: 6.8%
H: 2.07%
C: -9.98%
sciences meeting trial results
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Published: 2024-04-02 (Crawled : 16:00) - biospace.com/
KRBP | $2.64 -90.21% 360
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.0%
favorable biopharma trial
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
PRFX 4 d | $0.841 -5.48% -5.8% 23K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -8.95%
prf-110 trial
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
CRBP | $35.5 -5.94% -6.37% 220K
|
Health Technology
|
| O: -5.1%
H: 9.2%
C: 0.67%
first trial
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.6%
H: 2.8%
C: 2.25%
cancer trials trial
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M
|
Health Technology
|
| O: -0.82%
H: 2.96%
C: 1.74%
trial
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NRBO | $3.09 2.32% 2.27% 39K
|
Health Technology
|
| O: -1.2%
H: 0.0%
C: -1.46%
da-1241 treatment pharmaceuticals trial
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
CADL | $6.03 2.03% 1.99% 670K
|
| Email alert
Add to watchlist
can-3110 drug presentation update trial therapeutics glioblastoma
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 16:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: -2.26%
H: 20.0%
C: 17.67%
pharmaceuticals meeting trial
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
RVPH | $3.02 -1.31% -1.32% 78K
|
|
| O: -3.08%
H: 3.7%
C: 0.0%
brilaroxazine meeting schizophrenia trial
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -0.97%
H: 1.18%
C: -0.98%
gfh009 brukinsa cell collaboration trial therapy study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.